The Journal of Immunology, Vol 143, Issue 9 2939-2947, Copyright © 1989 by American Association of Immunologists

ARTICLES

Specificity of peptide binding by the HLA-A2.1 molecule

N Shimojo, WL Maloy, RW Anderson, WE Biddison and JE Coligan
Molecular Immunology Section, National Institute of Neurological Disorders and Bethesda, MD 20892.

The HLA-A2 molecule contains a putative peptide binding site that is bounded by two alpha-helices and a beta-pleated sheet floor. Previous studies have demonstrated that the influenza virus matrix peptide M1 55- 73 can sensitize target cells for lysis by HLA-A2.1-restricted virus- immune CTL and can induce CTL that can lyse virus-infected target cells. To assess the specificity of peptide binding by the HLA-A2.1 molecule, we examined the ability of seven variant M1 peptides to be recognized by a panel of M1 55-73 peptide-specific HLA-A2.1-restricted CTL lines. The results demonstrate that five out of the seven variant M1 55-73 peptides could be recognized by A2.1-restricted M1 55-73 peptide-specific CTL lines. The two variant peptides that were not recognized by any CTL could bind to HLA-A2.1 as indicated by their ability to compete for presentation of the M1 55-73 peptide. In addition, 5 of a panel of 24 unrelated peptides tested could also compete for M1 55-73 presentation by HLA-A2.1. One peptide derived from the sequence of a rotavirus protein could sensitize HLA-A2.1+ targets for lysis by M1 55-73 peptide-specific CTL. We conclude from these studies that: 1) the HLA-A2.1 molecule can bind a broad spectrum of peptides; 2) T cells selected for the ability to recognize one peptide plus a class I molecule can actually recognize an unrelated peptide presented by that same class I molecule; and 3) a stretch of three adjacent hydrophobic amino acids may be an important common feature of peptides that can bind to HLA-A2.1.

This article has been cited by other articles:

				C. Palena, D. E. Polev, K. Y. Tsang, R. I. Fernando, M. Litzinger, L. L. Krukovskaya, A. V. Baranova, A. P. Kozlov, and J. Schlom The Human T-Box Mesodermal Transcription Factor Brachyury Is a Candidate Target for T-Cell-Mediated Cancer Immunotherapy Clin. Cancer Res., April 15, 2007; 13(8): 2471 - 2478. [Abstract] [Full Text] [PDF]

				H. Wedemeyer, E. Mizukoshi, A. R. Davis, J. R. Bennink, and B. Rehermann Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells J. Virol., December 1, 2001; 75(23): 11392 - 11400. [Abstract] [Full Text]

				L. K. Selin, S. M. Varga, I. C. Wong, and R. M. Welsh Protective Heterologous Antiviral Immunity and Enhanced Immunopathogenesis Mediated by Memory T Cell Populations J. Exp. Med., November 2, 1998; 188(9): 1705 - 1715. [Abstract] [Full Text] [PDF]

				A. Bertoletti, F. Cham, S. McAdam, T. Rostron, S. Rowland-Jones, S. Sabally, T. Corrah, K. Ariyoshi, and H. Whittle Cytotoxic T Cells from Human Immunodeficiency Virus Type 2-Infected Patients Frequently Cross-React with Different Human Immunodeficiency Virus Type 1 Clades J. Virol., March 1, 1998; 72(3): 2439 - 2448. [Abstract] [Full Text] [PDF]